Saladax Biomedical develops and commercializes novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCare™ assays improves the efficacy of existing drugs through optimized dosing. Saladax’s initial focus is oncology, with a portfolio of 13 chemotherapy drug dose management assays in various stages of development. Three MyCare assays are currently offered to the oncology community: My5-FU™, MyPaclitaxel™ and MyDocetaxel™. Our MyCare line also serves the central nervous system (CNS) field, with two antipsychotic drug dose management assays.
The Company’s MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories for multiple applications. It offers the potential to achieve benefits such as optimized dosing, solving narrow therapeutic index problems and achieving optimal efficacy/toxicity balance. This makes Saladax a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing the multiple risks and challenges they face in the new drug development process.
The Company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified.